5 Park Plaza
Suite 1750
Irvine, CA 92614
United States
(949) 354-6499
https://www.aeonbiopharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 10
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Marc Forth | Principal Financial Officer, President, CEO & Director | 948,75k | S.O. | 1971 |
Mr. Alex Wilson | Executive VP, Chief Legal Officer & Corporate Secretary | 517,4k | S.O. | 1987 |
Dr. Chad K. Oh M.D. | Chief Medical Officer | 561k | S.O. | 1959 |
Ms. Jennifer Sy | Principal Accounting Officer | S.O. | S.O. | 1985 |
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
L’ISS Governance QualityScore de AEON Biopharma, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..